6月17日周二盘前，中概股脑再生科技（RGC）再度大涨28.22%，延续了周一的强势涨势。昨日，该股收盘暴涨283.13%，创下历史新高，总市值突破296亿美元。
脑再生科技近期表现亮眼，主要得益于其在脑机接口领域的布局。公司此前宣布其新一代神经调控芯片通过FDA临床试验审批，并将与全球顶尖医疗机构梅奥诊所合作，开展帕金森病治疗研究。这一消息引发了投资者对脑机接口技术前景的热烈关注。
值得注意的是，脑再生科技刚完成了38比1的股票拆分，这一举措增加了公司股票的流动性，可能吸引了更多的投资者参与交易。然而，投资者也应当注意，该公司目前仍处于早期阶段，尚未产生任何收入。在2024财年财报中，公司甚至表示"可能永远无法盈利"。因此，尽管股价表现抢眼，投资者仍需谨慎评估相关风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.